bepridil has been researched along with Brugada Syndrome in 3 studies
Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.
Brugada Syndrome: An autosomal dominant defect of cardiac conduction that is characterized by an abnormal ST-segment in leads V1-V3 on the ELECTROCARDIOGRAM resembling a right BUNDLE-BRANCH BLOCK; high risk of VENTRICULAR TACHYCARDIA; or VENTRICULAR FIBRILLATION; SYNCOPAL EPISODE; and possible sudden death. This syndrome is linked to mutations of gene encoding the cardiac SODIUM CHANNEL alpha subunit.
| Excerpt | Relevance | Reference |
|---|---|---|
| "It has been reported that bepridil prevents ventricular fibrillation (VF) in patients with Brugada syndrome, but the comparative efficacy with and without mutation in the SCN5A gene has not been elucidated." | 9.14 | Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with Brugada syndrome with and without SCN5A mutation. ( Hata, Y; Ito, H; Kohno, K; Kusano, KF; Miura, D; Morita, H; Murakami, M; Nagase, S; Nakagawa, K; Nakamura, K; Nishii, N; Ohe, T; Tada, T; Tanaka, M; Toh, N, 2010) |
| "It has been reported that bepridil prevents ventricular fibrillation (VF) in patients with Brugada syndrome, but the comparative efficacy with and without mutation in the SCN5A gene has not been elucidated." | 5.14 | Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with Brugada syndrome with and without SCN5A mutation. ( Hata, Y; Ito, H; Kohno, K; Kusano, KF; Miura, D; Morita, H; Murakami, M; Nagase, S; Nakagawa, K; Nakamura, K; Nishii, N; Ohe, T; Tada, T; Tanaka, M; Toh, N, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aizawa, Y | 1 |
| Yamakawa, H | 1 |
| Takatsuki, S | 1 |
| Katsumata, Y | 1 |
| Nishiyama, T | 1 |
| Kimura, T | 1 |
| Nishiyama, N | 1 |
| Fukumoto, K | 1 |
| Tanimoto, Y | 1 |
| Tanimoto, K | 1 |
| Mitamura, H | 1 |
| Ogawa, S | 1 |
| Fukuda, K | 1 |
| Murakami, M | 1 |
| Nakamura, K | 1 |
| Kusano, KF | 1 |
| Morita, H | 1 |
| Nakagawa, K | 1 |
| Tanaka, M | 1 |
| Tada, T | 1 |
| Toh, N | 1 |
| Nishii, N | 1 |
| Nagase, S | 1 |
| Hata, Y | 1 |
| Kohno, K | 1 |
| Miura, D | 1 |
| Ohe, T | 1 |
| Ito, H | 1 |
| Chinushi, M | 1 |
| Iijima, K | 1 |
| Sato, A | 1 |
| Furushima, H | 1 |
1 trial available for bepridil and Brugada Syndrome
| Article | Year |
|---|---|
Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with Brugada syndrome with and without SCN5A mutation.
Topics: Adult; Aged; Aged, 80 and over; Bepridil; Brugada Syndrome; Calcium Channel Blockers; Electrocardiog | 2010 |
2 other studies available for bepridil and Brugada Syndrome
| Article | Year |
|---|---|
Efficacy and safety of bepridil for prevention of ICD shocks in patients with Brugada syndrome and idiopathic ventricular fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Bepridil; Brugada Syndrome; Cohort Studies; Defibrillators, Imp | 2013 |
Short-coupling premature ventricular complexes from the left ventricle triggered isoproterenol-resistant electrical storm in a patient with Brugada syndrome.
Topics: Adult; Anti-Arrhythmia Agents; Bepridil; Brugada Syndrome; Cardiotonic Agents; Electrocardiography; | 2013 |